Today: 3 April 2026
Barclays shares in focus as bank makes first stablecoin bet with Ubyx stake
7 January 2026
1 min read

Barclays shares in focus as bank makes first stablecoin bet with Ubyx stake

London, January 7, 2026, 07:51 GMT — Premarket

Barclays (BARC.L) shares were set for focus ahead of the London open on Wednesday after the bank said it had bought a stake in U.S. stablecoin-settlement firm Ubyx, its first investment in a stablecoin-related company. Barclays declined to disclose the size of the investment; Ubyx runs a clearing system for stablecoins, digital tokens designed to track mainstream currencies, and Barclays was one of 10 banks including Goldman Sachs and UBS that said in October it was exploring a stablecoin pegged to G7 currencies. The stock ended Tuesday up 0.36% at 488.40 pence, close to a 492.95 pence 52-week high, and is up about 79% over the past year, Hargreaves Lansdown data showed. Reuters+1

Stablecoins have moved from a niche crypto tool to a settlement instrument that large financial firms are studying for payments and market plumbing. That matters now because banks are looking for faster ways to move money and settle trades, while regulators press them to keep new token-based activity within tight controls.

For Barclays investors, the immediate issue is less the economics of a minority stake and more what it signals about strategy. Tokenisation — turning money or assets into digital tokens on a blockchain — can create fee opportunities, but it can also bring execution risk, scrutiny and higher compliance spend.

A regulatory notice showed Barclays bought back 2,454,192 shares on Tuesday at a volume-weighted average price of 488.9595 pence — the average paid across the day’s trades — and plans to cancel them. The bank said it has repurchased 58,908,604 shares since the programme began on Oct. 23. Investegate

The wider backdrop for bank stocks has also been shaped by a debate among regulators about easing parts of post-crisis capital rules. Jose Manuel Campa, outgoing chair of the European Banking Authority, told Reuters that “well-capitalised banks are much better at taking lending decisions.” Reuters

With Barclays trading near its 52-week high, the 493 pence area and the round 500 pence mark are in focus on short-term charts. A softer open would put attention back on the high-480s, where the bank has been buying stock through its repurchase programme.

The next scheduled catalyst is Barclays’ final results on Feb. 10, according to its financial diary on London South East. Investors will be watching for updates on capital returns, costs and credit quality, and for any clearer outline of how the Ubyx investment fits into the bank’s payments and digital-money plans. London South East

But stablecoin projects often take years to reach scale, and rules around digital tokens are still evolving across markets. Any regulatory pushback or a renewed chill in crypto trading could limit the strategic value of the stake and leave little near-term impact on earnings.

Stock Market Today

  • Vertex Pharmaceuticals (VRTX) Stock Dips Amid Market Gains Ahead of Earnings
    April 2, 2026, 7:35 PM EDT. Vertex Pharmaceuticals (VRTX) stock fell 0.28% to $476.37, underperforming the S&P 500's 0.27% gain. Despite recent underperformance, VRTX shares rose 3.2% over the past month, outperforming the medical sector's 4.14% loss. Investors eye the firm's upcoming November 4 earnings report, with consensus estimates projecting a 1.23% rise in earnings per share (EPS) to $4.13 and revenue growth of 7.79% to $2.68 billion. The annual outlook shows mixed signals with an anticipated EPS drop but revenue up 8.72%. Vertex maintains a high forward P/E ratio of 7,704.84 and PEG ratio of 581.72, far above industry averages, indicating premium valuation. The stock carries a Zacks Rank #3 (Hold), while its medical industry ranks in the top 30%, reflecting relative strength amid cautious investor sentiment.
GSK plc stock in focus as hepatitis B drug bepirovirsen clears key Phase 3 hurdle
Previous Story

GSK plc stock in focus as hepatitis B drug bepirovirsen clears key Phase 3 hurdle

BP stock slides nearly 5% after Evercore downgrade; oil slump raises buyback questions
Next Story

BP stock slides nearly 5% after Evercore downgrade; oil slump raises buyback questions

Go toTop